CPH just picked up 10 grams of pharma grade psilocybin
Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.
This supply should take it through to Phase III clinical trials for micro-dosing treatment of mental health and is a big de-risking event.
We are big believers in the psychedelics industry and the potential to transform mental health, and CPH’s imminent psychedelics acquisition captured our attention.
We entered CPH as a trade in October 2020 and were pleasantly surprised by the run it had through to the end of 2020.
CPH’s acquisition target company just picked up 20mg of synthetic psilocybin for phase c trials to test for it’s about
We decided to maintain a large position after the late 2020 share price run, and we then increased our holding at 19c in March.
CPH is a medical cannabis company, set to acquire a psychedelics company in the coming weeks.
We are big believers in the psychedelics industry and the potential to transform mental health, and this CPH’s target acquisition captured our attention.
Mindmed, capped at A$1.2BN and Compass Pathways, capped at A$1.8BN are the shining lights of the psychedelics industry.
A few weeks back, we were hoping Mindmed would rocket on its NASDAQ listing and sweep CPH along with it - but Mindmed has traded sideways since its NASDAQ launch. It is still up 37% in the last 3 weeks on other exchanges - a pretty big result for a $1BN plus capped company.
We don't think the nascent psychedelics industry is as well understood in Australia yet as there has not been a local success story on the ASX.
CPH is not shy of promoting, and intends to list on the OTC in the coming weeks - opening up the story to the much larger North American market.
Today CPH’s target acquisition company doubled its supply of synthetic psilocybin, taking total inventory to 22.3 grams.
Why is having 22.3 grams of synthetic psilocybin important?
Psilocybin is a psychoactive substance, and currently an illegal drug in Canada - so sourcing a legal, high quality supply is extremely difficult.
For listed public companies, getting a reliable supply can be one of the biggest barriers to advancing clinical trials and demonstrating efficacy of their product.
It's a massive industry bottleneck as everyone scrambles into the industry, so having a confirmed supply is a big de-risking event for CPH.
In comparison, Compass Pathways used 10g for Phase I trials, and needs another 32 g for Phase II clinical trials - our calcs from its Investor Presentation.
At 22.3 grams, CPH’s target acquisition company is now one of the largest holders of single batch GMP grade synthetic psilocybin in Canada.
CPH intends to run Clinical Trials on microdosing, which will require less psilocybin than Compass - and the amount CPH has got ensures it has enough for up to Phase III trials.
The more psilocybin, the more people can participate in clinical trials, the more data the company can gather, the more value can be generated.
What are we waiting for next?
In the coming weeks we are expecting:
- Completion of the acquisition of the psychedelics company
- OTC listing and increased North American awareness of the stock
- Hopefully some more revenue generating cannabis sales
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
